Cargando…

Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by chemotherapy resistance and a median survival of less than 2 years. Here, we investigated the pharmacological effects of the novel highly specific cyclin-dependent kinase 9 (CDK9) inhibitor LDC526 and its clinically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johansson, Patricia, Dierichs, Laura, Klein-Hitpass, Ludger, Bergmann, Anke K., Möllmann, Michael, Menninger, Sascha, Habenberger, Peter, Klebl, Bert, Siveke, Jens T., Dührsen, Ulrich, Choidas, Axel, Dürig, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570784/ https://www.ncbi.nlm.nih.gov/pubmed/33117517 http://dx.doi.org/10.1177/2040620720933761

Ejemplares similares

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia
por: Johansson, Patricia, et al.
Publicado: (2018)

Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia
por: Göthert, Joachim R., et al.
Publicado: (2018)

White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy
por: Dahl, Edgar, et al.
Publicado: (2022)

Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic Leukemia
por: Göbel, Maria, et al.
Publicado: (2013)

Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas
por: Johansson, Patricia, et al.
Publicado: (2016)

Epigenetic Silencing of the Circadian Clock Gene CRY1 is Associated with an Indolent Clinical Course in Chronic Lymphocytic Leukemia
por: Hanoun, Maher, et al.
Publicado: (2012)

Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing
por: Johansson, Patricia, et al.
Publicado: (2020)

CpG stimulation of chronic lymphocytic leukemia cells induces a polarized cell shape and promotes migration in vitro and in vivo
por: Dampmann, Maria, et al.
Publicado: (2020)

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
por: Brägelmann, Johannes, et al.
Publicado: (2017)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

T-cell Prolymphocytic Leukemia, Cerebriform Variant
por: Carvalho, José, et al.
Publicado: (2021)

Synthesis, Biological Evaluation, and Binding Mode of a New Class of Oncogenic K‐Ras4b Inhibitors
por: Jeuken, Stephan, et al.
Publicado: (2022)

T-cell Prolymphocytic Leukemia Presenting as Red Eye
por: Alwadani, Fahad
Publicado: (2011)

Advances in the understanding and management of T-cell prolymphocytic leukemia
por: Laribi, Kamel, et al.
Publicado: (2017)

An illustrative case of B-cell prolymphocytic leukemia
por: Jain, Ankur, et al.
Publicado: (2020)

Bilateral tonsillar infiltration of T‐cell prolymphocytic leukemia
por: Bertaggia, Ilaria, et al.
Publicado: (2019)

Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia
por: Varadarajan, Indumathy, et al.
Publicado: (2022)

De-Novo B-Cell Prolymphocytic Leukemia
por: Menakuru, Sasmith R., et al.
Publicado: (2023)

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment
por: Gutierrez, Marc, et al.
Publicado: (2023)

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
por: Lücking, Ulrich, et al.
Publicado: (2017)

An Association Between Hypoplastic Myelodysplastic Syndrome and T-Prolymphocytic Leukaemia
por: Arathi, C A, et al.
Publicado: (2011)

T-cell Prolymphocytic Leukemia with Cutaneous Involvement as the Presenting Feature
por: Ashturkar, Amrut V, et al.
Publicado: (2012)

T‐cell prolymphocytic leukemia and tuberculosis: a puzzling association
por: Cervera, Pascale, et al.
Publicado: (2017)

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
por: Hampel, Paul J., et al.
Publicado: (2021)

T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches
por: Colon Ramos, Ana, et al.
Publicado: (2021)

Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia
por: Siu, Sarah Y., et al.
Publicado: (2016)

Small cell variant of T-cell prolymphocytic leukemia with atypical presentation
por: Park, Joowon
Publicado: (2018)

Auer Rod-Like Inclusions in B-Cell Prolymphocytic Leukemia
por: Zhao, Yantian, et al.
Publicado: (2019)

Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia
por: Tian, Shulan, et al.
Publicado: (2021)

Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact
por: Braun, Till, et al.
Publicado: (2021)

Delayed Diagnosis of T-Cell Prolymphocytic Leukemia: Approach to Chronic Lymphocytosis
por: Geres, Hana, et al.
Publicado: (2023)

Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia
por: Meeuse, Jan J., et al.
Publicado: (2007)

Concomitant T-cell prolymphocytic leukemia and visceral leishmaniasis: A case report
por: Liao, Hongyan, et al.
Publicado: (2018)

A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia
por: Merdin, Alparslan, et al.
Publicado: (2017)

CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2020)

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
por: Toutah, Krimo, et al.
Publicado: (2021)

Dual Inhibition of GSK3β and CDK5 Protects the Cytoskeleton of Neurons from Neuroinflammatory-Mediated Degeneration In Vitro and In Vivo
por: Reinhardt, Lydia, et al.
Publicado: (2019)

De novo chronic lymphocytic leukemia/prolymphocytic leukemia or B-cell prolymphocytic leukemia? The importance of integrating clinico-morphological and immunophenotypic findings in distinguishing chronic lymphoproliferative diseases with circulating phase
por: Chowdhury, Zachariah, et al.
Publicado: (2020)

Characterization of bursa subacromialis-derived mesenchymal stem cells
por: Steinert, Andre F., et al.
Publicado: (2015)

The MEC1 and MEC2 Lines Represent Two CLL Subclones in Different Stages of Progression towards Prolymphocytic Leukemia
por: Rasul, Eahsan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cih93i2ccpsva92i9dnfu2mebn